Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib StudyPhilippe Rousselot,Hyacinthe Johnson-Ansah,Françoise Huguet,Laurence Legros,Martine Escoffre-Barbe,Martine Gardembas,Pascale Cony-Makhoul,Valérie Coiteux,Laurent Sutton,Wajed Abarah,Camille Pouaty,Jean Michel Pignon,Bachra Choufi,Sorin Visanica, Bénédicte Deau,Stephane Bouchet,Francois Guilhot,Francois-Xavier Mahon,Laure Morisset,Jean-Michel Cayuela, Benjamin ManeglierFundamental & Clinical Pharmacology(2016)引用 28|浏览56暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要